Skip to main content
Walvax Biotechnology Co.,Ltd. logo

Walvax Biotechnology Co.,Ltd. — Investor Relations & Filings

Ticker · 300142 ISIN · CNE100000WN2 LEI · 300300H82R2DIQXA8N24 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,790 across all filing types
Latest filing 2021-06-04 Director's Dealing
Country CN China
Listing Shenzhen Stock Exchange 300142

About Walvax Biotechnology Co.,Ltd.

https://www.walvax.com

Walvax Biotechnology Co.,Ltd. is a biopharmaceutical enterprise specializing in the research, development, production, and distribution of vaccines and other biological products. The company focuses on modern biotechnology to address public health challenges through a diverse portfolio of preventive vaccines. Key products include the 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13), the bivalent human papillomavirus (HPV) vaccine, and various combination vaccines for meningitis and Haemophilus influenzae type b (Hib). Walvax operates advanced R&D platforms and manufacturing facilities that comply with international quality standards. The company is actively involved in the development of next-generation vaccine technologies, including mRNA and recombinant protein platforms, aiming to provide affordable and high-quality immunization solutions for global markets.

Recent filings

Filing Released Lang Actions
关于公司部分董事、高级管理人员向成都喜云企业管理合伙企业（有限合伙）转让股份的公告
Director's Dealing Classification · 100% confidence The document is an announcement regarding the transfer of shares by certain directors and senior management of the company to another entity. It details the number of shares transferred, the prices, and the shareholding changes before and after the transfer. It also includes compliance statements about the legality of the share transfer and mentions that the shares were obtained through a stock option incentive plan. This type of document is a report of personal share transactions by company directors and executives, which fits the definition of Director's Dealing (DIRS). The document length is over 5,000 characters and contains detailed data about the transactions, so it is not a mere announcement or certification. Therefore, the correct classification is DIRS.
2021-06-04 Chinese
关于2018年股票期权激励计划部分已授予股票期权注销完成的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from a company regarding the cancellation of part of its previously granted stock options under a 2018 stock option incentive plan. It references board meetings approving the cancellation, regulatory compliance, and confirmation by the securities registration authority. The content focuses on a specific corporate action related to stock options and does not contain financial statements, earnings data, or detailed financial analysis. It is not a full report but an announcement of a corporate action related to share-based incentives. This fits best under the category of Regulatory Filings (RNS), as it is a regulatory announcement about stock option cancellations and does not fit other more specific categories like Share Issue/Capital Change or Director's Dealing, since it concerns cancellation of stock options due to employee departure rather than new share issuance or insider trades.
2021-06-03 Chinese
关于公司董事所持公司股份变动的公告
Director's Dealing Classification · 100% confidence The document is an announcement regarding changes in shareholdings by company directors, specifically detailing the transfer of shares by two directors, including the number of shares transferred, prices, and compliance with relevant regulations. It does not contain financial statements, earnings data, or management discussion. It is focused on insider share transactions by directors. Therefore, it fits the category of Director's Dealing (DIRS). The document length is short and it is not a report or announcement of a report publication, but a direct disclosure of share transactions by directors.
2021-06-03 Chinese
关于2020年股票期权激励计划部分已授予股票期权注销完成的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the cancellation of part of a stock option incentive plan due to an employee's departure. It details the number of stock options canceled and references compliance with relevant regulations. There is no financial report, earnings data, or management discussion. The document is a formal announcement about a capital-related change (stock option cancellation) but does not describe a new share issue or repurchase. It fits best under Capital/Financing Update (CAP) as it relates to changes in the company's capital structure through stock option cancellations.
2021-06-03 Chinese
关于合作研发的重组新型冠状病毒疫苗（黑猩猩腺病毒载体）获得药物临床试验批件的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company regarding the approval of a clinical trial permit for a new recombinant COVID-19 vaccine. It includes regulatory approval details, mentions the clinical trial phases, and cautions investors about the impact on company performance. The document is short (849 characters) and serves as an official announcement of a regulatory milestone rather than a financial report or detailed management discussion. It does not contain financial data, earnings, or management changes. It fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement about drug trial approval and related compliance information.
2021-05-28 Chinese
第四届董事会第二十四次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board of directors meeting of Yunnan Watson Biotechnology Co., Ltd. It details decisions on stock option cancellations, adjustments to stock option exercise prices, capital increase and amendments to the company charter, and loan applications by a subsidiary. The document includes voting results and mentions that some matters will be submitted to the shareholders' meeting for approval. It is not a full financial report, earnings release, or audit report, but rather a disclosure of board meeting decisions. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors or senior management. The document length is 3286 characters, which is consistent with a detailed board meeting announcement rather than a full report. Therefore, the appropriate classification is MANG with high confidence.
2021-05-27 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.